Clinical trial NCT02280642: Alternate Dosing Schedules Study for HPV Vaccine (ADS)
Official title: Alternate Dosing Schedules Study for HPV Vaccine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cervical Cancer
Genital Warts
Keywords: Human papillomavirus
Cervical cancer
Genital warts
Vaccine
Immunogenicity
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Centers for Disease Control and Prevention
First posted: 2014-10-31
Enrollment: 331
Sex: FEMALE
Minimum age (years): 9
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adolescent females attending primary care clinics in central North Carolina

Brief summary: The purpose of this study was to determine if delayed dosing of recombinant human papillomavirus (HPV) quadrivalent (Types 6, 11, 16, and 18) vaccine in 9-18 year old girls elicited an equivalent immune response (geometric mean titers to HPV 6,11,16, and 18 as measured one month after receipt of a 3rd dose of HPV vaccine) when compared to vaccine delivered according to the recommended dosing schedule.

This was a prospective observational study of healthy 9-18 year old female patients receiving either a second or third dose of HPV vaccine as part of their well child care. Immune responses to HPV types 6, 11, 16 and 18 were measured both before and 1 month after the third dose of HPV vaccine with the purpose of comparing the immune responses to HPV vaccine when administered at naturally occurring longer dosing intervals to the immune response to HPV vaccine when administered as routinely recommended.

In addition, girls receiving a 3rd dose of HPV vaccine as well as concomitantly administered vaccines by injection were randomized to receive either the HPV vaccine first or their concomitantly administered vaccines first. Pain following vaccination was assessed in each arm using the Faces Pain Scale - Revised.

Please note: This record refers only to the observational portion of the study. Please refer to NCT00862810 for the results of the randomized portion of the study.


Eligibility criteria: Inclusion Criteria:

1. A healthy, medically well female between the ages of 9 - 18 years. (Must be between 9 years and younger than 19 years of age) at time of enrollment
2. Must be receiving either a 3rd dose of HPV vaccine (All Groups) or a 2nd dose of HPV vaccine (Group 2 only)

   * For Group 1 - EITHER 1) The second dose of HPV vaccine must not have been administered and it must be within the specified dosing interval for the second dose of HPV vaccine (\> 90 days since the first dose of HPV vaccine) OR 2) The second dose of HPV vaccine must have been administered \> 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose of HPV vaccine (\> 60 days - \< 180 days since the second dose of HPV)
   * For Group 2 - The second dose of HPV vaccine must have been administered \> 30 days and \< 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (\> 180 days since the second dose of HPV)
   * For Group 3 - The second dose of HPV vaccine must have been administered \> 30 days and \< 90 days after the first dose of HPV vaccine and it must be within the specified dosing interval for the third dose (\> 60 days - \< 180 days since the second dose of HPV)
   * For Group 4- The second dose of HPV vaccine must have been administered \> 90 days after the first dose of HPV of HPV vaccine and it must be within the specified dosing interval for the third dose (\> 180 days since the second dose of HPV)
3. Ability and willingness to participate in the study by providing written informed assent. Verbal assent is acceptable for subjects less than 12 years of age.
4. Parent/guardian provides informed consent
5. Anticipated ability and willingness to complete all study visits and evaluations

Exclusion Criteria:

1. Unable to comply with the study protocol
2. Receipt of three or more doses of HPV vaccine or receipt of doses of HPV vaccine outside the pre-specified time windows
3. Receipt of blood and or blood products (including immunoglobulin) in the past 3 months or anticipated receipt during the study period
4. Receipt of a live virus vaccine (varicella virus containing vaccine, any measles, mumps, or rubella virus containing vaccine such as MMR, or yellow fever vaccine but not including live attenuated influenza virus vaccine) within 4 weeks of receipt of the 3rd dose of HPV vaccine or anticipated receipt of a live virus vaccine within 4 weeks after the 3rd dose of HPV vaccine
5. History of any physical, mental, or developmental disorder that study personnel believe may hinder a participant's ability to comply with the study requirements
6. History of malignancy or confirmed or suspected immunodeficient condition such as HIV infection
7. Receipt of or history of receipt of any medications or treatments that affect the immune system, such as immune globulin, interferon, immunomodulators, cytotoxic drugs or other drugs known to be frequently associated with significant major organ toxicity since six months prior to the first HPV vaccine dose. Receipt of long-term (greater than or equal to 2 weeks) potentially immunosuppressive corticosteroid use within six months prior to HPV vaccine dose 1 and enrollment or anticipated receipt during the study period. Specifically, potentially immunosuppressive corticosteroids are any parenteral corticosteroid, high dose (\>800 mcg/day) beclomethasone dipropionate or equivalent medication. Nasal and topical steroids are allowed.
8. Current or former participation in HPV vaccine related research.
9. Receipt of an investigational or alternate HPV vaccine

Primary outcomes:
measure: HPV 6 GMT
timeFrame: 1 month following 3rd dose of HPV vaccine
measure: HPV 11 GMT
timeFrame: 1 month following 3rd dose of HPV vaccine
measure: HPV 16 GMT
timeFrame: 1 month following 3rd dose of HPV vaccine
measure: HPV 18 GMT
timeFrame: 1 month following 3rd dose of HPV vaccine
Secondary outcomes:
Other outcomes:
Locations:
city: Chapel Hill
country: United States
facility: Chapel Hill Pediatrics
state: North Carolina
city: Durham
country: United States
facility: Duke Children's Primary Care
state: North Carolina
city: Durham
country: United States
facility: Durham Pediatrics
state: North Carolina
Study officials:
affiliation: Duke University
name: Emmanuel B Walter, MD
role: PRINCIPAL_INVESTIGATOR
References: